Skip to content

Efficacy and safety of Scar Antipruritic cream in the treatment of hypertrophic scar after burn and scald: a randomized controlled trial.

Efficacy and safety of Scar Antipruritic cream in the treatment of hypertrophic scar after burn and scald

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003439
Enrollment
Unknown
Registered
2020-06-30
Start date
2020-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperplastic scar after burn

Interventions

Sponsors

Wuxi Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Hypertrophic scar formed after burn and scald for more than 6 months without signs of regression; 2. The scar is raised on the surface of skin, hard and smooth; 3. It has the clinical symptoms of continuous growth, redness, pain and itching, and has no tendency of self-healing and can not subside by itself; 4. The lesions did not exceed the original damage margin, and the boundary was regular. There was no infiltration into the surrounding normal tissues and did not grow like crab feet; 5. Scar length >= 8cm, thickness >= 2mm; 6. Patients who have not received glucocorticoid injection, other laser therapy and other invasive treatment in recent one year; 7. Patients aged 18-55 years, male or female, volunteer; 8. Patients and their families agree and sign the informed consent for special treatment.

Exclusion criteria

Exclusion criteria: 1. The lesions are keloid or keloid tendency, such as exceeding the original damage edge, irregular boundary, infiltrating into surrounding normal tissues and growing like crab feet; 2. Pregnant or lactating women; 3. Patients with systemic diseases (liver and kidney insufficiency, cardiopulmonary dysfunction, hyperlipidemia, hypercholesterolemia, anemia, etc.); 4. Patients with serious skin diseases, such as psoriasis, scleroderma, etc; 5. Patients who quit the experiment before the end of treatment, such as death, loss of follow-up, etc.

Design outcomes

Primary

MeasureTime frame
VSS;

Secondary

MeasureTime frame
Microbiota in scar;VRS;

Countries

China

Contacts

Public ContactFeng Zhang

Wuxi Third People's Hospital

zf9958@163.com+86 15301516836

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026